

2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: a cardiac imager's perspective in the assessment of stable chest pain

The 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain (1) was developed by the American College of Cardiology and the American Heart Association in conjunction with some imaging societies and other organizations, in an attempt to put together the best evidence for the evaluation of patients with acute or stable chest pain. In regards to stable chest pain/suspected stable ischemic heart disease, some key points have been raised in a prior editorial (2): “1) imaging should be used selectively; 2) testing should be avoided when the diagnostic yield is low; 3) test layering should be avoided when possible; and 4) lower cost options should be prioritized when outcomes are similar”.

In this path, the guideline recommends the initial assessment of pretest risk probability to define the need of diagnostic testing, and then choose the most appropriate test. As prior risk scores have been shown to overestimate the probability of coronary artery disease (CAD), especially in women (3, 4), a modified, more contemporary risk score (5) was incorporated, which suggests the use of coronary artery calcium score (CAC) to refine the clinical risk stratification. It is worth noting that the probability estimates refer to patients with chest pain or dyspnea, the latter being a possible anginal equivalent.

Briefly, according to the guidelines, for patients with stable chest pain and no known CAD categorized as low risk, besides the possibility of deferring diagnostic testing, both CAC and exercise testing without imaging were considered reasonable first-line tests, the former for excluding calcified plaque and identifying patients with a low likelihood of obstructive CAD, and the latter for excluding myocardial ischemia and determining functional capacity in patients with an interpretable electrocardiogram.

Among intermediate- to high-risk patients with stable chest pain and no known CAD, coronary computed tomography (CT) angiography (CTA) or stress imaging (stress echocardiography, positron emission tomography [PET]/single-photon emission computed tomography [SPECT], or cardiac magnetic resonance [CMR]) are recommended as options.

Among patients with stable chest pain with known CAD, medical treatment with deferred testing is an option, but if there are persistent symptoms, CTA or invasive angiography (especially if high-risk CAD or frequent angina are present) or stress testing are recommended.

It is worth noting that these guidelines were not endorsed by the American Society of Nuclear Cardiology (ASNC), even though that organization provided input during the construction of the guideline. As stated by Thompson et al. (6), “Although the members of the Board of Directors appreciated a number of positive things about this document and appreciated the collaborative effort on the part of ACC and AHA leadership, the Board ultimately concluded that the shortcomings were too great to warrant endorsement (...) There are many excellent, evidence-based recommendations in the new guideline. There also are some troubling recommendations and some omissions that, in the end, ASNC cannot support”. Among the issues were raised by the ASNC, two are especially concerning: 1) the role given to fractional flow reserve (FFR)-CT in the guidelines, as it currently still has limited availability, efficacy, level of adoption, and substantial cost; and 2) the grouping of “functional tests” (exercise treadmill test, stress echocardiography, myocardial perfusion SPECT or PET, CMR), which have different characteristics, particular advantages and disadvantages, accuracies, and cannot be viewed as a unique group.

Address for Correspondence: Andrea De Lorenzo, University Hospital Clementino Fraga Filho, Postgraduate program, Federal University of Rio de Janeiro, National Institute of Cardiology, Rio de Janeiro, Brazil

Email: andlorenzo@hotmail.com

Received: 22.10.2022 Accepted: 23.10.2022

Copyright ©2022 Heart, Vessels and Transplantation

doi: 10.24969/hvt.2022.346

These are, indeed, relevant points, which do not remove the merits of the guideline for the systematization of the assessment of patients with chest pain, but claim for careful thinking instead of only following flowcharts. It is crucial to also consider patient characteristics and preferences, local expertise, access to and availability of different tests in the decision-making process in the assessment of patients with stable chest pain.

Andrea De Lorenzo

University Hospital Clementino Fraga Filho,
Postgraduate program,

Federal University of Rio de Janeiro,
National Institute of Cardiology, Rio de Janeiro, Brazil

Peer-review: Internal

Conflict of interest: None to declare

Authorship: A.De L.

Acknowledgement and funding: None to declare

References

1 Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: A report of the American College of Cardiology/American Heart Association Joint

Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2021. Doi: /10.1016/j.jacc.2021.07.053.

2. Blankstein R, Gulati M, Jaber WA, Bullock-Palmer RP, Bhatt DL, Shaw LJ. The 2021 Chest Pain Guideline: A Revolutionary New Paradigm for Cardiac Testing, *JACC: Cardiovasc Imag* 2022; 15: 140-4.

3 Baskaran L, Danad I, Gransar H, Hartaigh BO, Schulman-Marcus J, Lin FY, et al. A comparison of the updated Diamond-Forrester, CAD Consortium, and CONFIRM history-based risk scores for predicting obstructive coronary artery disease in patients with stable chest pain: the SCOT-HEART Coronary CTA cohort. *J Am Coll Cardiol Cardiovasc Imag* 2019; 12: 1392–400.

4 Bittencourt MS, Hulten E, Polonsky TS, Hoffman U, Nasir K, Abbara S, et al. European Society of Cardiology-recommended coronary artery disease consortium pretest probability scores more accurately predict obstructive coronary disease and cardiovascular events than the Diamond and Forrester score: the Partners registry. *Circulation* 2016; 134: 201–11.

5 Juarez-Orozco LE, Saraste A, Capodanno D, Prescott E, Ballo H, Bax JJ, et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. *Eur Heart J Cardiovasc Imaging* 2019;20: 1198–207.

6 Thompson RC, Al-Mallah MH, Beanlands RSB, caLNON da, Dorbala Sh, Phillips LM, et al. ASNC's thoughts on the AHA/ACC chest pain guidelines. *J Nucl Cardiol* 2022; 29: 19–23.